Acadian Asset Management
NKTR icon

Acadian Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Acadian Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,989
Closed -$141K – 2153
2026
Q1 		$141K Sell
1,989
-70,252
-97% -$4M ﹤0.01% 1675
2025
Q4 		$3.05M Buy
72,241
+44,906
+164% +$2.51M 0.01% 795
2025
Q3 		$1.55M Sell
27,335
-393,623
-94% -$13M ﹤0.01% 952
2025
Q2 		$10.9M Sell
420,958
-65,824
-14% -$739K 0.02% 419
2025
Q1 		$4.96M Buy
486,782
+6,709
+1% +$87.7K 0.01% 502
2024
Q4 		$6.69M Buy
480,073
+103,081
+27% +$1.82M 0.02% 441
2024
Q3 		$7.35M Buy
376,992
+51,352
+16% +$979K 0.02% 402
2024
Q2 		$6.05M Sell
325,640
-178,964
-35% -$3.77M 0.02% 459
2024
Q1 		$7.07M Sell
504,604
-16,650
-3% -$174K 0.02% 381
2023
Q4 		$4.42M Buy
521,254
+12,828
+3% +$97.2K 0.02% 493
2023
Q3 		$4.54M Buy
508,426
+215,358
+73% +$2.07M 0.02% 465
2023
Q2 		$2.53M Buy
293,068
+251,051
+597% +$2.68M 0.01% 632
2023
Q1 		$442K Buy
42,017
+40,465
+2,607% +$1.22M ﹤0.01% 1079
2022
Q4 		$52K Buy
+1,552
New +$75.1K ﹤0.01% 1574
2019
Q3 		– Sell
-21,269
Closed -$11.4M – 1965
2019
Q2 		$11.4M Buy
21,269
+13,627
+178% +$6.83M 0.05% 267
2019
Q1 		$3.85M Buy
7,642
+7,397
+3,019% +$4.38M 0.02% 507
2018
Q4 		$121K Sell
245
-461
-65% -$278K ﹤0.01% 1233
2018
Q3 		$646K Buy
+706
New +$603K ﹤0.01% 831

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management's NKTR Position: Q2 2026 in Review

Acadian Asset Management sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 1,989 shares — an estimated $141K sold.

Acadian Asset Management first reported a position in NKTR in Q3 2018 and held it in 18 quarters. The position peaked at $11.4M in Q2 2019. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Acadian Asset Management reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Acadian Asset Management sold 1,989 Nektar Therapeutics shares in Q2 2026, an estimated $141K.
  • Acadian Asset Management first reported a position in Nektar Therapeutics in Q3 2018 and held it in 18 quarters.
  • Acadian Asset Management's Nektar Therapeutics position peaked at $11.4M in Q2 2019.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.